Innate Pharma specializes in immuno oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body s own immune cells to recognize and kill cancer cells. The Company has pioneered the development of antibodies that block inhibitory checkpoint receptors on NK cells. Today, Innate Pharma has three first in class antibodies in clinical development in immuno oncology and a pipeline of preclinical candidates to novel targets and mechanisms. Its innovative approach has translated into alliances with leaders in the biopharmaceutical industry such as AstraZeneca, Bristol Myers Squibb, Novo Nordisk A/S and Sanofi. Based in Marseille, France, Innate Pharma had employees as at March , . The company is listed on Euronext Paris.
Quote | Innate Pharma (OTCMKTS:IPHYF)
Last: | $2.20 |
---|---|
Change Percent: | 0.0% |
Open: | $2.2 |
Close: | $2.20 |
High: | $2.2 |
Low: | $2.2 |
Volume: | 100 |
Last Trade Date Time: | 05/08/2024 03:00:00 am |
News | Innate Pharma (OTCMKTS:IPHYF)
Two abstracts on SAR443579 (IPH6101), ANKET ® platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager under development by partner Sanofi in blood cancer Two abstracts on IPH6501, Innate’s second generation ANKET ® for the treatment of relap...
2024-05-14 11:03:08 ET Innate Pharma S.A. (IPHA) Q1 2024 Results Conference Call May 14, 2024 08:00 AM ET Company Participants Henry Wheeler - Head, Investor Relations Herve Brailly - Interim Chief Executive Officer Sonia Quaratino - Chief Medical Officer Yan...
Message Board Posts | Innate Pharma (OTCMKTS:IPHYF)
Subject | By | Source | When |
---|---|---|---|
Stock_Tracker: Latest Innate Pharma (IPHYF) Headlines INNATE PHARMA : raises 20.3 million in a | Stock_Tracker | investorshangout | 03/10/2014 10:53:12 AM |
chartguy89: IPHYF 15.058 Stock Charts $IPHYF 1 Month Chart | chartguy89 | investorshangout | 03/08/2014 4:38:31 AM |
chartguy89: IPHYF Stock Charts Last: -0.78 Thursday, February 27, 2014 at 3:45:56 AM $IPHYF | chartguy89 | investorshangout | 02/27/2014 8:46:08 AM |
News, Short Squeeze, Breakout and More Instantly...
Two abstracts on SAR443579 (IPH6101), ANKET ® platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager under development by partner Sanofi in blood cancer Two abstracts on IPH6501, Innate’s second generation ANKET ® for the treatment of relap...
First preclinical data set for IPH45, a pre-IND anti-Nectin-4 Antibody Drug Conjugate, presented as an oral presentation at AACR 2024 Progression of Sanofi-developed NK Cell Engager SAR443579/IPH6101 to Phase 2 in blood cancers Five ASCO Annual Meeting 2024 abstracts: ...
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Tuesday, May 14, 2024, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress...